Last update 09 Jul 2025

CX-1026

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CX 1026, CX1026
Target
AXL x HDAC6 x VEGFR2
Action
inhibitors, antagonists
Mechanism
AXL inhibitors(AXL receptor tyrosine kinase inhibitors), HDAC6 inhibitors(Histone deacetylase 6 inhibitors), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Therapeutic Areas
NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]
Active Indication
Colonic CancerKidney NeoplasmsLiver Cancer+ [1]
Inactive Indication
Acute Myeloid LeukemiaNon-Small Cell Lung CancerStomach Cancer
Originator Organization
Beijing Konruns Pharmaceutical Co., Ltd.Beijing Konruns Pharmaceutical Co., Ltd.
Active Organization
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
Inactive Organization-
License Organization
Guangzhou Esa Biotech Co., Ltd.
Beijing Konruns Pharmaceutical Co., Ltd.Beijing Konruns Pharmaceutical Co., Ltd.
Drug Highest PhasePreclinical
First Approval Date-
Regulation-

Related

100 Clinical Results associated with CX-1026
Login to view more data
100 Translational Medicine associated with CX-1026
Login to view more data
100 Patents (Medical) associated with CX-1026
Login to view more data
100 Deals associated with CX-1026
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colonic CancerPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
29 May 2024
Kidney NeoplasmsPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
29 May 2024
Liver CancerPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
29 May 2024
Lung CancerPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
29 May 2024
Acute Myeloid LeukemiaPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
30 Jan 2022
Non-Small Cell Lung CancerPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
30 Jan 2022
Stomach CancerPreclinical
China
Beijing Konruns Biotechnology Co., Ltd.Beijing Konruns Biotechnology Co., Ltd.
30 Jan 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free